p70 S6 kinase inhibitor

p70 S6 kinase inhibitor is a preclinical-stage small molecule program being developed by Epigen Biosciences (in collaboration with the University of California, San Diego) for the treatment of Fragile X Syndrome (FXS). The program targets p70 S6 kinase (p70S6K), a downstream effector of both mTORC1 and ERK signaling pathways that plays a critical role in regulating translation. Dysregulated protein synthesis is a core molecular abnormality in FXS, and inhibition of p70S6K aims to normalize synaptic translation and correct behavioral and cognitive deficits. Lead candidates in this program include EPGN-2036 and EPGN-1370.

Other names

70 kDa ribosomal protein S6 kinase inhibitorp70 S6 kinase inhibitorp-70 S6 kinase inhibitorp 70 S6 kinase inhibitorp70 S6 kinase inhibitorsp-70 S6 kinase inhibitorsp 70 S6 kinase inhibitorsp70 S6K inhibitorp-70 S6K inhibitorp 70 S6K inhibitorp70 S6K inhibitorsp-70 S6K inhibitorsp 70 S6K inhibitors